Menu Search
Equities

Zevra Therapeutics Inc

1GDA:DEU

Zevra Therapeutics Inc

Actions
  • Price (EUR)4.20
  • Today's Change-0.04 / -0.94%
  • Shares traded250.00
  • 1 Year change-9.87%
  • Beta--
Data delayed at least 15 minutes, as of Apr 29 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

  • Revenue in USD (TTM)27.46m
  • Net income in USD-46.05m
  • Incorporated2014
  • Employees65.00
  • Location
    Zevra Therapeutics Inc1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION 34747United StatesUSA
  • Phone+1 (321) 939-3416
  • Fax+1 (319) 665-2577
  • Websitehttps://zevra.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ZVRA:NSQ since
announced		Transaction
value
Acer Therapeutics IncDeal completed31 Aug 202331 Aug 2023Deal completed-13.77%91.00m
Data delayed at least 15 minutes, as of Apr 30 2024 17:42 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.